Group photo at the semi-annual meeting of the joint steering committee of the HSCI’s collaboration with Boehringer Ingelheim in fibrosis research with the research project teams.
This past week, Harvard Stem Cell Institute (HSCI) hosted the semi-annual meeting of the joint steering committee and the project teams that are members of HSCI’s collaboration with Boehringer Ingelheim (BI) in fibrosis research. This three-year research collaboration was established in June, 2016 between the Germany-based global pharmaceutical company Boehringer Ingelheim and HSCI’s Harvard Fibrosis Network to foster the discovery of new ways to understand and treat fibrotic diseases.
Over two days, members of the Harvard and BI teams shared presentations and discussed their recent scientific progress, identified new areas for cooperation, and made plans for the future. BI is currently supporting the work of three research groups at Harvard and is interested in bringing additional projects into the collaboration.
The Harvard Fibrosis Network is a scientific collaborative of HSCI researchers led by Joseph Bonventre, HSCI Executive Committee member and Chief of the Renal Unit at Brigham and Women’s Hospital.